Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cardinal Health ( (CAH) ) has shared an announcement.
At its 2025 Annual Meeting of Shareholders on November 5, Cardinal Health elected 12 directors to its Board, approved executive compensation, and ratified Ernst & Young LLP as its auditor for the fiscal year ending June 30, 2026. These decisions reflect shareholder support for the company’s leadership and financial oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (CAH) stock is a Buy with a $225.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Spark’s Take on CAH Stock
According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.
Cardinal Health’s overall stock score is driven by strong earnings call performance and robust cash flow, offset by financial leverage concerns and potential overvaluation. The technical analysis indicates bullish momentum, but overbought conditions suggest caution. The valuation metrics reflect a high P/E ratio, indicating potential overvaluation.
To see Spark’s full report on CAH stock, click here.
More about Cardinal Health
Cardinal Health, Inc. operates in the healthcare industry, providing pharmaceutical and medical products and services. The company focuses on improving the cost-effectiveness of healthcare and operates globally, serving hospitals, pharmacies, and other healthcare providers.
Average Trading Volume: 2,547,452
Technical Sentiment Signal: Buy
Current Market Cap: $46.41B
Find detailed analytics on CAH stock on TipRanks’ Stock Analysis page.